BLFS

BioLife Solutions Inc. (BLFS) | Rumor.io

BioLife Solutions

BLFS

Attention (50-day avg)0%

Attention rank (50-day avg)#2,970

Bullish sentiment (50-day avg)90%

Price to earnings ratio38.4

Market capitalization1.9B

Earnings per share1.02

Dividend yield (TTM)—

Revenue (annual)96.2M

Net income (annual)-4.6M

Social

What share of all stock conversation is about BLFS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Jul 22

Repligen Corp ($RGEN) will acquire BioLife Solutions ($BLFS) in a cash-and-stock deal valued at about $1.5 billion, expanding its presence in the cell therapy market.
BioLife stockholders will receive $11.25 per share in cash and 0.144 shares of Repligen common stock, valuing the company at $31 per share in cash and stock.
The deal is expected to close in Q4 2026 and become accretive to adjusted EPS in the first year.

Generated by AI

Sentiment

Of the messages about BLFS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	57.94% -15.97
Bearish	—	0%	0% 0	42.06% +15.97

Bullish· Mar 23

BioLife Solutions' ($BLFS) recent acquisition and earnings have led to increased analyst optimism, with upgrades and price target raises from firms like Maxim, Benchmark, and KeyCorp.
The company's Q4 revenue growth, driven by biopreservation media sales and the addition of SciSafe biostorage revenue, has been cited as a key factor in the upgrades and price target increases.
BioLife Solutions is expected to graduate from a niche player to a company with significant scale, with many analysts predicting strong growth and increased profitability in the future.

Bearish· Jul 12

The asset has seen a significant drop in value, with a 12.66% decline in one week.
The post suggests that the abundance of short positions is stalling the trade, as there are no new buyers to cover these shorts.
The asset's volume has dried up, with sellers having completed their sales, and the focus is now on who will start covering their shorts first.

Generated by AI

Topics

Of the messages about BLFS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	92.31%	85.47%
Technical Analysis	—	100%	7.69%	5.13%
Analysts	—	0%	0%	6.41%
Controversies	—	0%	0%	1.71%
Earnings	—	0%	0%	1.28%
Macro	—	0%	0%	0%

Jul 22

Repligen $RGEN will acquire BioLife Solutions $BLFS for about $1.5 billion, valuing the company at $31 per share in cash and stock.
BioLife stockholders will receive $11.25 per share in cash and 0.144 shares of Repligen common stock, for a total value of $31 per share.
The deal is expected to close in Q4 2026 and become accretive to adjusted EPS in the first year, expanding Repligen's presence in the fast-growing cell therapy market.

Generated by AI

Community

Of the messages about BLFS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	15.75%
Newcomers	—	100%	100%	84.25%

Regulars· Mar 17

The company's Q4 results beat revenue expectations, and FY23 revenue guidance is in-line, with the regulars expecting revenue growth to accelerate mid-FY23.
There is a disagreement among regulars about the accuracy of Wall Street's initial estimates for Q1 and FY23 EBITDA, with some believing the estimates are low.
The company's stock price has been impacted by an analyst downgrade, with the regulars noting a PT lower to $27.00 at Stephens.

Newcomers· Jul 22

Newcomers are focused on the acquisition of BioLife Solutions by Repligen, with the deal valued at approximately $1.5 billion.
The acquisition is expected to expand Repligen's presence in the cell therapy market, and BioLife stockholders will receive a cash-and-stock deal valued at $31 per share.
The transaction is expected to close in Q4 2026 and become accretive to adjusted EPS in the first year after the acquisition.

Generated by AI

Diamond Hill Capital, a First Eagle Investment Management company, issued its Q2 2026 investor letter for its “Small Cap Strategy”. The letter can be downloaded here. The strategy returned 24.01% in the second quarter, outperforming the Russell 2000 Index’s 21.49% return. Performance was positively affected by stock selection in health care and industrials, while the Fund’s underweight position […]

25d agoYahoo Finance

Biolife Solutions stock hits 52-week high at 35.36 USD

1mo agoInvesting.com

BioLife Solutions (BLFS) Is Up 7.2% After Swinging From Loss To Q2 Profit - What's Changed

1mo agoYahoo Finance

BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Surpass Estimates

1mo agoYahoo Finance

Also Discussed

Investors talking about BLFS also mention

#	Name	Attention
1	Cryoport Inc.CYRX	0%0
2	BCLI - Brainstorm Cell Therapeutics Inc.	——
3	Vericel CorporationVCEL	0%0
4	MRNS - Marinus Pharmaceuticals, Inc.	——
5	Azenta, Inc.AZTA	0%0
6	Element Solutions Inc.ESI	0%0
7	CareDx IncCDNA	0.01%+0.01
8	Merit Medical Systems, Inc.MMSI	0%0
9	PDF Solutions, Inc.PDFS	0%new
10	Harvard Bioscience Inc.HBIO	0%0

BioLife Solutions Inc.

Healthcare
Medical Instruments & Supplies

BioLife Solutions Inc. is a life sciences tools company that develops, manufactures, and markets bioproduction products and services for the cell and gene therapy industry. BioLife Solutions Inc. focuses on helping protect the viability and integrity of biologic materials throughout collection, processing, storage, transport, and thawing. Its product portfolio includes biopreservation media, cell-processing consumables, cryogenic storage containers, automated thawing systems, and cold-chain management solutions. These offerings are used by cell therapy developers, biopharmaceutical companies, contract development and manufacturing organizations, biobanks, and research institutions that work with sensitive living cells and other advanced biologic materials. The company serves customers across the United States and international markets, supporting research, clinical development, and commercial manufacturing workflows in regenerative medicine and related fields.

Website

Location

3303 Monte Villa Parkway

Bothell, WA, 98021

United States

Social

What share of all stock conversation is about BLFS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Jul 22

Repligen Corp ($RGEN) will acquire BioLife Solutions ($BLFS) in a cash-and-stock deal valued at about $1.5 billion, expanding its presence in the cell therapy market.
BioLife stockholders will receive $11.25 per share in cash and 0.144 shares of Repligen common stock, valuing the company at $31 per share in cash and stock.
The deal is expected to close in Q4 2026 and become accretive to adjusted EPS in the first year.

Generated by AI

Sentiment

Of the messages about BLFS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	57.94% -15.97
Bearish	—	0%	0% 0	42.06% +15.97

Bullish· Mar 23

BioLife Solutions' ($BLFS) recent acquisition and earnings have led to increased analyst optimism, with upgrades and price target raises from firms like Maxim, Benchmark, and KeyCorp.
The company's Q4 revenue growth, driven by biopreservation media sales and the addition of SciSafe biostorage revenue, has been cited as a key factor in the upgrades and price target increases.
BioLife Solutions is expected to graduate from a niche player to a company with significant scale, with many analysts predicting strong growth and increased profitability in the future.

Bearish· Jul 12

The asset has seen a significant drop in value, with a 12.66% decline in one week.
The post suggests that the abundance of short positions is stalling the trade, as there are no new buyers to cover these shorts.
The asset's volume has dried up, with sellers having completed their sales, and the focus is now on who will start covering their shorts first.

Generated by AI

Topics

Of the messages about BLFS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	92.31%	85.47%
Technical Analysis	—	100%	7.69%	5.13%
Analysts	—	0%	0%	6.41%
Controversies	—	0%	0%	1.71%
Earnings	—	0%	0%	1.28%
Macro	—	0%	0%	0%

Jul 22

Repligen $RGEN will acquire BioLife Solutions $BLFS for about $1.5 billion, valuing the company at $31 per share in cash and stock.
BioLife stockholders will receive $11.25 per share in cash and 0.144 shares of Repligen common stock, for a total value of $31 per share.
The deal is expected to close in Q4 2026 and become accretive to adjusted EPS in the first year, expanding Repligen's presence in the fast-growing cell therapy market.

Generated by AI

Community

Of the messages about BLFS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	15.75%
Newcomers	—	100%	100%	84.25%

Regulars· Mar 17

The company's Q4 results beat revenue expectations, and FY23 revenue guidance is in-line, with the regulars expecting revenue growth to accelerate mid-FY23.
There is a disagreement among regulars about the accuracy of Wall Street's initial estimates for Q1 and FY23 EBITDA, with some believing the estimates are low.
The company's stock price has been impacted by an analyst downgrade, with the regulars noting a PT lower to $27.00 at Stephens.

Newcomers· Jul 22

Newcomers are focused on the acquisition of BioLife Solutions by Repligen, with the deal valued at approximately $1.5 billion.
The acquisition is expected to expand Repligen's presence in the cell therapy market, and BioLife stockholders will receive a cash-and-stock deal valued at $31 per share.
The transaction is expected to close in Q4 2026 and become accretive to adjusted EPS in the first year after the acquisition.

Generated by AI

BioLife Solutions

Social

Jul 22

Sentiment

Bullish· Mar 23

Bearish· Jul 12

Topics

Jul 22

Community

Regulars· Mar 17

Newcomers· Jul 22

News

Biolife Solutions stock hits 52-week high at $38.10

BioLife Solutions merger with Repligen advances as antitrust waiting period ends

Diamond Hill Bets on BioLife Solutions’ (BLFS) High Switching Cost

Biolife Solutions stock hits 52-week high at 35.36 USD

BioLife Solutions (BLFS) Is Up 7.2% After Swinging From Loss To Q2 Profit - What's Changed

BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Surpass Estimates

Also Discussed

BioLife Solutions Inc.

Company Information

Location

News

Biolife Solutions stock hits 52-week high at $38.10

BioLife Solutions merger with Repligen advances as antitrust waiting period ends

Diamond Hill Bets on BioLife Solutions’ (BLFS) High Switching Cost

Biolife Solutions stock hits 52-week high at 35.36 USD

BioLife Solutions (BLFS) Is Up 7.2% After Swinging From Loss To Q2 Profit - What's Changed

BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Surpass Estimates

Also Discussed

Social

Jul 22

Sentiment

Bullish· Mar 23

Bearish· Jul 12

Topics

Jul 22

Community

Regulars· Mar 17

Newcomers· Jul 22